A detailed history of Alliancebernstein L.P. transactions in Keros Therapeutics, Inc. stock. As of the latest transaction made, Alliancebernstein L.P. holds 158,205 shares of KROS stock, worth $2.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
158,205
Previous 150,462 5.15%
Holding current value
$2.5 Million
Previous $6.88 Million 33.6%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$41.68 - $58.07 $322,728 - $449,636
7,743 Added 5.15%
158,205 $9.19 Million
Q2 2024

Aug 14, 2024

BUY
$44.58 - $66.89 $2.61 Million - $3.92 Million
58,604 Added 63.8%
150,462 $6.88 Million
Q1 2024

May 14, 2024

BUY
$41.26 - $70.48 $2.92 Million - $4.99 Million
70,738 Added 334.93%
91,858 $6.08 Million
Q2 2023

Aug 15, 2023

BUY
$37.26 - $51.01 $179,593 - $245,868
4,820 Added 29.57%
21,120 $848,000
Q4 2022

Feb 14, 2023

BUY
$39.45 - $51.77 $55,230 - $72,478
1,400 Added 9.4%
16,300 $782,000
Q3 2022

Nov 15, 2022

SELL
$27.8 - $40.12 $2,780 - $4,011
-100 Reduced 0.67%
14,900 $561,000
Q2 2022

Aug 15, 2022

BUY
$26.03 - $67.04 $72,884 - $187,712
2,800 Added 22.95%
15,000 $414,000
Q4 2021

Feb 14, 2022

SELL
$36.95 - $62.89 $107,155 - $182,381
-2,900 Reduced 19.21%
12,200 $714,000
Q2 2021

Jul 30, 2021

BUY
$42.4 - $70.11 $63,600 - $105,165
1,500 Added 11.03%
15,100 $641,000
Q1 2021

May 06, 2021

SELL
$54.0 - $75.28 $48,600 - $67,752
-900 Reduced 6.21%
13,600 $837,000
Q4 2020

Feb 08, 2021

BUY
$36.0 - $82.74 $270,000 - $620,550
7,500 Added 107.14%
14,500 $1.02 Million
Q3 2020

Nov 12, 2020

BUY
$27.04 - $62.21 $24,336 - $55,989
900 Added 14.75%
7,000 $270,000
Q2 2020

Aug 13, 2020

BUY
$20.08 - $40.39 $122,487 - $246,379
6,100 New
6,100 $229,000

Others Institutions Holding KROS

About Keros Therapeutics, Inc.


  • Ticker KROS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,757,000
  • Market Cap $408M
  • Description
  • Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...
More about KROS
Track This Portfolio

Track Alliancebernstein L.P. Portfolio

Follow Alliancebernstein L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alliancebernstein L.P. with notifications on news.